Emerging evidence for the role of CCR-2 and CCR-5 receptors in human inflammatory diseases, arteriosclerosis and NASH has led to growing interest in developing CCR-2 and CCR-5 selective antagonists.53 This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.